893 related articles for article (PubMed ID: 25575865)
1. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
2. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy.
Choi JW; Kim HA; Nam K; Na Y; Yun CO; Kim S
J Control Release; 2015 Dec; 220(Pt B):691-703. PubMed ID: 26437261
[TBL] [Abstract][Full Text] [Related]
3. Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus.
Moon CY; Choi JW; Kasala D; Jung SJ; Kim SW; Yun CO
Biomaterials; 2015 Feb; 41():53-68. PubMed ID: 25522965
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration.
Choi JW; Dayananda K; Jung SJ; Lee SH; Kim D; Hu J; Bae YH; Yun CO
Acta Biomater; 2015 Dec; 28():86-98. PubMed ID: 26365317
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
6. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus.
Kang YA; Shin HC; Yoo JY; Kim JH; Kim JS; Yun CO
Mol Ther; 2008 Jun; 16(6):1033-40. PubMed ID: 18398429
[TBL] [Abstract][Full Text] [Related]
7. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy.
Kwon OJ; Kang E; Choi JW; Kim SW; Yun CO
J Control Release; 2013 Aug; 169(3):257-65. PubMed ID: 23562633
[TBL] [Abstract][Full Text] [Related]
9. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
10. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression.
Lee CH; Kasala D; Na Y; Lee MS; Kim SW; Jeong JH; Yun CO
Biomaterials; 2014 Jul; 35(21):5505-16. PubMed ID: 24731708
[TBL] [Abstract][Full Text] [Related]
11. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
12. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.
Yoon AR; Hong J; Kim M; Yun CO
Sci Rep; 2018 Feb; 8(1):2233. PubMed ID: 29396500
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
Kim J; Li Y; Kim SW; Lee DS; Yun CO
Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
[TBL] [Abstract][Full Text] [Related]
15. Using a magnetic field to redirect an oncolytic adenovirus complexed with iron oxide augments gene therapy efficacy.
Choi JW; Park JW; Na Y; Jung SJ; Hwang JK; Choi D; Lee KG; Yun CO
Biomaterials; 2015 Oct; 65():163-74. PubMed ID: 26164117
[TBL] [Abstract][Full Text] [Related]
16. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
17. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
18. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
19. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
20. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]